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Background: The goal of this study was to investigate the anti-angiogenic activity of a novel peptide H-RN,
derived from the hepatocyte growth factor kringle 1 domain (HGF K1), in a mouse model of corneal
neovascularization. The anti-angiogenic effect of H-RN on vascular endothelial growth factor (VEGF)-stimulated cell
proliferation, cell migration and endothelial cell tube formation was assessed in vitro using Human Umbilical Vein
Endothelial Cells (HUVECs) and in vivo using a mouse cornea micropocket assay. Apoptosis and cell cycle arrest
were assessed by flow cytometry. A scrambled peptide was used as a negative control.
Results: H-RN effectively inhibited VEGF-stimulated HUVEC proliferation, migration and tube formation on Matrigel,
while a scrambled peptide exerted no effect. In the mouse model of corneal angiogenesis, VEGF-stimulated
angiogenesis was significantly inhibited by H-RN compared to a scrambled peptide that had no such activity. VEGF
protected HUVECs from apoptosis, while H-RN inhibited this protective effect of VEGF. VEGF significantly increased
the proportion of cells in the S phase compared to control treated cells (p<0.05). Treatment with H-RN (1.5 mM)
induced the accumulation of cells in G0/G1 phase, while the proportion of cells in the S phase and G2/M phase
decreased significantly compared to control group (p<0.05).
Conclusions: H-RN has anti-angiogenic activity in HUVECs and in a mouse model of VEGF-induced corneal
neovascularization. The anti-angiogenic activity of H-RN was related to apoptosis and cell cycle arrest, indicating a
potential strategy for anti-angiogenic treatment in the cornea.
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The transparency and refraction properties of a normal,
healthy cornea are predominantly mediated by its
avascularity. However, many pathological processes
affecting the cornea, including trauma, inflammation,
infection, toxicity and nutritional insults, may lead to
corneal neovascularization [1]. While this process may be
beneficial in wound healing, clearance of infections and
arresting progressive immune-mediated corneal melts,
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reproduction in any medium, provided the orgrowing into the normally vascular-free cornea tissue,
bleeding into the cornea and causing lipid deposition, tis-
sue swelling and scarring [2]. Corneal neovascularization
may significantly impair visual acuity and the immune
privilege of the cornea, and may also worsen the prognosis
of corneal transplantation [3-6]. The prevalence of corneal
neovascularization ranges from 125,000-470,000 individ-
uals in the population wearing soft contact lenses [7] and
is associated with the second most common cause of
blindness globally, and with the most common form of
corneal blindness in developed countries [8].
Clinical ophthalmologists have been challenged with the
treatment of sight-threatening corneal neovascularization
for over 100 years [8]. However, because age-related. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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population in developed world, the anterior segment
neovascularization inhibition still lags behind anti-
angiogenesis at the posterior pole of the eye [8]. The
current clinical treatment for corneal angiogenesis primarily
involves direct anti-angiogenesis agents (bevacizumab,
ranibizumab and pegaptanib), indirect anti-angiogenesis
agents (anti-inflammatory steroids and cyclosporine A)
[8,9], laser photocoagulation, fine-needle diathermy, photo-
dynamic therapy [10] and conjunctival, limbal or amniotic
membrane transplantation. However, regular application of
corticosteroids may increase the risk of infection and
induce cataracts and glaucoma [9]. Other methods of treat-
ment often require multiple treatment sessions with risks
of severe complication arising, since significantly more laser
energy is needed than that used for the treatment of
choroidal neovascularization. Furthermore, photodynamic
therapy, which is reported to significantly inhibit corneal
neovascularization, only blocks existing neovascularization,
but does not prevent pathological angiogenesis. Currently,
treatments targeting the molecular mediators of angiogen-
esis are widely studied and represent the ideal choice for
therapy. VEGF is a major mediator of the angiogenic
process. Numerous therapeutic strategies targeting VEGF
are being studied [11,12]. New therapeutic agents, including
pegaptanib, ranibizumab and particularly bevacizumab, are
reported to be effective in inhibiting corneal neovas-
cularization. However, the extremely high annual treatment
cost of these agents has limited their widespread use and
systemic adverse events have been reported [13,14].
The design and development of peptides to inhibit angio-
genesis is an important area in anti-angiogenic drug devel-
opment [15]. In comparison to proteins, peptides display
lower immunogenicity, higher solubility in water, stable
production methods, improved consistency between
batches and are superior at targeting and penetrating
tumors [15]. Previously, we identified a novel peptide,
H-RN, derived from the hepatocyte growth factor kringle
1 domain (HGF K1), and demonstrated that it has anti-
angiogenic activity to retinal neovascularization in a mouse
model [16]. In the current study, we further investigated
the ability of H-RN to inhibit corneal neovascularization
and possible anti-angiogenesis mechanisms. Our study may
lead to new potential drug discoveries and the development
of novel treatments for pathological retinal and corneal
angiogenesis.
Results
H-RN inhibits HUVEC proliferation
To investigate the effect of H-RN on HUVEC proliferation,
cells were exposed to VEGF (100 ng/ml) alone and in com-
bination with various concentrations of H-RN or scrambled
peptide for 24 h. In comparison with control cells, treat-
ment with VEGF alone induced a significant increase in cellproliferation (Figure 1, p<0.05). Treatment of cells with
increasing concentrations of H-RN peptide resulted in a
significant inhibition of cell proliferation (p<0.05), reaching
maximal inhibition at 1 mM H-RN. In contrast, treatment
of cells with scrambled peptide had no inhibitory effect
(Figure 1, p>0.05). These results indicate that H-RN impairs
VEGF-induced HUVEC proliferation.
HUVECs migration towards VEGF is inhibited by H-RN
Next, we investigated the ability of H-RN to affect the
migration of HUVECs using Transwell migration assays.
Compared to control, VEGF significantly stimulated
HUVEC migration through the porous membrane of
Transwell chambers (p<0.001). Various concentrations
of H-RN (1 nM, 10 nM, 100 nM and 1 μM) were then
added to test the inhibitory effect of this peptide on
VEGF-induced HUVECs migration. Scrambled peptide was
added as control. The results showed that H-RN signifi-
cantly inhibited cell migration, especially at 100 nM and
1 μM (p<0.001) compared with control scrambled peptide
(p>0.05) (Figure 2).
H-RN inhibits HUVEC tube formation in Matrigel
We next assessed the ability of H-RN to affect tube forma-
tion in Matrigel. As shown in Figure 3, tube formation was
strongly stimulated by VEGF (100 ng/ml). HUVEC tube
formation was effectively inhibited following treatment with
H-RN, especially at concentrations of 100 μM and above
(p<0.001, Figure 3). In contrast, scrambled peptide did not
inhibit VEGF-induced endothelium tube formation at any
concentration (p>0.05, Figure 3).
H-RN inhibits corneal angiogenesis in a mouse model
To investigate the effect of H-RN in vivo, we investigated
the effect of H-RN on corneal angiogenesis. The growth of
new capillary vessels from the corneal limbus towards
implanted pellets containing VEGF or VEGF combined
with peptides was assessed 7 days post-implantation. No
new vessels were observed in pellets containing PBS only.
Corneal neovascularization towards a pellet containing
VEGF was vigorous. In contrast, neovascularization
towards pellets containing both VEGF and H-RN was
significantly inhibited compared to VEGF only, particularly
at 5 μg H-RN (Figure 4). For quantitative analysis, the
vessel area was calculated according to the maximal vessel
length and clock hours. The vessel area decreased signifi-
cantly in the H-RN group when compared with VEGF
alone (Table 1, p<0.05). These results demonstrate that
H-RN exhibits an inhibitory effect on VEGF-induced angio-
genesis in the mouse cornea.
The effect of H-RN on the anti-apoptosis activity of VEGF
HUVECs were starved overnight and treated with various
agents and apoptosis was analyzed by flow cytometry.
Figure 1 H-RN inhibits human umbilical vein endothelial cell (HUVEC) proliferation while scrambled peptide exerts no effect. Following
starvation, HUVECs were incubated with vascular endothelial growth factor (VEGF) (100 ng/ml) and various concentrations of H-RN or scrambled
peptide for 24 h. Cell proliferation was significantly inhibited by H-RN, especially at 1 mM. Scrambled peptide had no inhibitory activity on
HUVECs at various concentrations (*p<0.05, each condition versus VEGF group).
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rant represent viable cells. Early apoptotic cells (annexin
V-FITC +/PI-) located in the bottom right quadrant repre-
sent early apoptotic cells. Following treatment of HUVECs
withVEGF (100 ng/ml), early apoptotic HUVECs decreased
from 9.35 ± 0.27% to 4.76 ± 0.41%. However, exposure of
cells to increasing concentrations of H-RN, led to an
increase in the percentage of early apoptotic cells to 5.62 ±
0.14% and 9.50 ± 0.51% (p<0.001, versus VEGF only group)
(Figure 5). These results demonstrate that VEGF protects
HUVECs from apoptosis, but that H-RN may inhibit
this effect.
H-RN induces cell cycle arrest of HUVECs in G0/G1 phase
To examine the effect of H-RN on cell growth, HUVECs
were incubated with VEGF or H-RN for 24 h and cell cycle
was assessed by PI staining and flow cytometry. Treatment
of HUVECs with VEGF significantly increased the propor-
tion of cells in the S phase (15.73% vs 8.70%, p<0.05), and
in G2/M phase (11.50% vs 9.78%, p<0.05) compared to
untreated control cells. Treatment of cells with H-RN
(1.5 mM) led to accumulation of cells in the G0/G1 phase
(89.20% vs 81.53%, p<0.05) and a significant decrease in the
proportion of cells in S phase (3.75% vs 8.70%, p<0.05)
and G2/M phase, compared to control untreated cells
(Figure 6).Discussion
Corneal neovascularization may be caused by several
pathogenic conditions, including inflammatory, ischemic,
degenerative or traumatic diseases of the cornea and loss
of the limbal stem cell barrier. To date, numerous models
of corneal angiogenesis have been developed. Thermal
injury and alkali-burn models have been utilized in many
studies, since these are easy to perform and corneal
neovascularization may be conveniently observed [17].
Inflammation is the major mechanism of cornea angio-
genesis in these models and these models were predomin-
antly used in studies focused on inflammation. Infectious
keratitis and corneal ulcers, which brought unstable
experimental results and difficulties to precise quantitative
analysis, are also commonly seen in these models. Mouse
tumor models induce corneal neovascularization by
intrastromal implantation of tumor cells in the rat or
mouse cornea, where vessel growth is stimulated by
tumor-secreted angiogenic factors, inflammation or
immunologic mediators [18]. We previously reported the
anti-angiogenic activity of H-RN in a choroid-retinal
endothelial cell line (RF/6A), in the chick chorioallantoic
membrane and in a mouse model of oxygen-induced
retinopathy [16].
In the present study, we investigated the anti-angiogenic
effect of H-RN in VEGF-induced corneal neovascular-
Figure 2 Effect of peptides on the migration of HUVECs stimulated by VEGF. HUVECs were pre-incubated with different concentrations of
peptides in the upper chamber for 30 min before stimulation with VEGF (100 ng/ml) in the lower chamber. After incubation for 24 h, the
migratory activity of cells was estimated. H-RN inhibited migration of HUVECs. Scrambled peptide did not inhibit migration up to 1 μM.
(*p<0.05; each condition versus VEGF group).
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cornea micropocket assay, which is dependent on direct
stimulation of neovascularization rather than indirect
stimulation by inflammation or tumors. Our results
obtained from both in vitro and in vivo models
were highly reproducible and easily quantifiable [19]. In
addition, VEGF was used as a direct angiogenesis stimula-
tor in the models, thus providing meaningful results for
the evaluation of an anti-VEGF and anti-angiogenic
reagent.
Previously, we reported a new peptide derived from HGF,
H-RN, which exhibited anti-angiogenic activity in a
choroid-retinal endothelial cell line (RF/6A) and in the
chick chorioallantoic membrane, as well as in a mouse
model of oxygen-induced retinopathy [16]. In the present
study, we investigated the anti-angiogenic activity of H-RN
on corneal neovascularization. HUVECs were used for
in vitro studies, and the effects of H-RN on VEGF-
stimulated proliferation, cell migration and endothelial cell
tube formation were investigated. Similar results were
found as those obtained from our in vitro study of RF/6A
cells. H-RN significantly inhibited HUVEC proliferation,
migration and tube formation stimulated by VEGF. The
inhibitory effects were particularly intense at high
concentrations, though not dose-dependent. The scrambledpeptide did not show any inhibitory effect at any concentra-
tion. In the mouse cornea micropocket assay, we found
that VEGF significantly stimulated corneal angiogenesis.
Neovascularization derived from the corneal limbus
developed towards VEGF-containing pellets, with bushy
and thick vessels migrating towards and over the surface of
the white pellet. This growth was significantly inhibited
following administration of H-RN. We infer that H-RN
has the potential for treating pathological corneal neovas-
cularization, and sustained release delivery may be an
effective drug delivery option, although further investigation
of H-RN pharmacokinetics is still required.
Li et al. [20] recently reported that topical administra-
tion of KH906, a recombinant human soluble VEGF
receptor fusion protein, was capable of significantly
inhibiting angiogenesis in an alkali burn corneal neovas-
cularization rabbit model by topical administration.
KH906 was administrated in three different concen-
trations; 5 mg/ml, 10 mg/ml and 20 mg/ml. Rabbits
received topical administration (50 μl) of the different
solutions four times daily for 14 days. Corneal neovas-
cularization was analyzed 10 and 14 days after chemical
cauterization. In this study, corneal neovascularization
was significantly reduced in KH906-treated groups
compared to control treated animals. Compared to the
Figure 3 Inhibitory effects of H-RN on HUVEC differentiation into capillary structures. HUVECs were starved overnight and pre-incubated
with different concentrations of H-RN and scrambled peptide for 30 min. VEGF (100 ng/ml) was added for peptide-treated and VEGF groups, and
cells were seeded into Matrigel-coated wells. A, no-VEGF; B, 100 ng/ml VEGF; C, 100 ng/ml VEGF + 1 mM H-RN; D, 100 ng/ml VEGF + 1 mM
scrambled peptide. VEGF (100 ng/ml) strongly stimulated HUVEC tube formation. H-RN significantly inhibited VEGF-stimulated HUVEC tube
formation, particularly at 1mM. Scrambled peptide did not show inhibitory effects on HUVEC tube formation (magnification ×200). E: Quantitative
analysis of tube formation under different experimental conditions using Image Program Plus software. Values represent the mean tube lengths
from three independent experiments (*p<0.05, each condition versus VEGF control group).
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quantity applied in Li’s study is much higher (250 μg vs
5 μg), indicating that H-RN has a much lower effective
concentration than KH-906. Furthermore, the treatment
cycle of H-RN is significantly shorter than KH-906 (7 d vs
14 d), and the production cost of H-RN is also lower than
KH-906. In this study, the level of VEGF in the cornea inKH906-treated groups was significantly decreased. In our
study, we found that the ability of H-RN to inhibit the
anti-apoptotic activity of VEGF and to induce G0/G1
phase cell cycle arrest is related to its anti-angiogenesis
properties. Taken together, this demonstrates that both
H-RN and KH-906 inhibit neovascularization through an
anti-VEGF mechanism.
Figure 4 C57BL/6 mouse corneas 7 days after implantation with pellets (asterisks) containing different reagents. A, phosphate buffered
saline (PBS); B, 160 ng VEGF; C, 160 ng VEGF and 1 μg H-RN; D, 160 ng VEGF and 5 μg H-RN. VEGF pellets induced a strong neovascular response,
originating from the corneal limbal vessels and reaching the pellet. Pellets containing VEGF and 1 μg H-RN also induced a neovascular response,
but this was less intense. Pellets containing VEGF and 5 μg H-RN resulted in a mild vascular response compared to VEGF group.
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vascular endothelial cell apoptosis [21]. We infer that
H-RN may inhibit the anti-apoptosis activity of VEGF, as
demonstrated by flow cytometric analysis of apoptosis. It is
well established that VEGF inhibits endothelial cells apop-
tosis via activation of the PI3K signaling pathway [21] and
by upregulating the expression of Bcl-2 and A1 [22],
important anti-apoptosis genes. Additional studies are
required to determine whether H-RN inhibits activation of
the PI3K signaling pathway or the expression of Bcl-2 and
A1. We further investigated the effect of H-RN on the cell
cycle of HUVECs, which may relate to its inhibitory effect
on endothelial cell proliferation. We observed a G0/G1
phase arrest in H-RN treated cells, indicating that H-RN
inhibits DNA replication of HUVECs. Cyclin, cyclin
dependent kinase (CDK) [23] and cyclin dependent kinase
inhibitor (CDKI) [24] are critical factors regulating the cellTable 1 Quantitative analysis of cornea
neovascularization in different groups
Group (n=8) Maximal vessel
length (mm)
Clock hours Vessel area
(mm2)
PBS 0 0 0
VEGF 1.16 ± 0.27 2.24 ± 0.25 1.62 ± 0.36
1μg H-RN 0.60 ± 0.16 2.04 ± 0.51 0.79 ± 0.36*
5μg H-RN 0.40 ± 0.18 1.28 ± 0.46 0.31 ± 0.18*
* p< 0.05 compared to VEGF group.cycle. Future studies will aim to investigate the relationship
between H-RN and these factors.Conclusions
In summary, we show that H-RN, a small peptide derived
from HGF, displays anti-angiogenic activity in HUVECs
and effectively inhibits VEGF-induced corneal angiogenesis
in a mouse model. While our study indicates that the anti-
angiogenic activity of H-RN is related to apoptosis and cell
cycle arrest, further studies investigating the mechanisms
underlying the anti-angiogenic activity of H-RN are
necessary.Methods
Cell culture and materials
HUVECs were obtained from the American Type Culture
Collection and maintained as monolayer cultures in
endothelial cell medium (ECM) supplemented with 10%
fetal bovine serum (FBS) at 37°C in 5% CO2. Human
VEGF was obtained from Sigma-Aldrich (USA). H-RN
(RNPRGEEGGPW, molecular weight: 1254.34 Da) and a
scrambled peptide were synthesized by solid phase pep-
tide synthesis using an automatic peptide synthesizer
(Symphony; Protein Technologies, Tucson, AZ). The end
product was characterized by high-performance liquid
chromatography (HPLC; LC-20A, SHIMADZU, Kyoto,
Figure 5 Flow cytometry analysis of plasma membranes with annexin V-FITC / PI double staining. A-D: representative photos of different
groups. A: control. Cells were incubated in serum-free medium for 24 h following overnight starvation. The numbers in upper left, upper right,
lower left and lower right quadrants represent the percentage of necrotic cells (annexin V positive, PI positive), advanced apoptotic cells
(annexin V negative, PI positive), viable cells (annexin V negative, PI negative) and early apoptotic cells (annexin V positive, PI negative)
respectively; B: VEGF. Cells were incubated in serum-free medium containing 100 ng/ml VEGF for 24 h following starvation; C: VEGF+150 μM
H-RN. Cells were pre-incubated with 150 μM H-RN for 30 min and VEGF (100 ng/ml) was added and incubated for 24 h; D: VEGF+1.5 mM H-RN.
Cells were pre-incubated in 1.5 mM H-RN for 30 min and VEGF (100 ng/ml) was added for 24 h; E: Quantitative analysis of apoptotic cells under
different experimental conditions. The values represent the mean percentages of apoptotic cells in different groups. (*p<0.05, each condition
versus VEGF control).
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Figure 6 Effect of H-RN on HUVEC cell cycle. Cells were incubated in serum-free medium with 100 ng/ml VEGF, 150 μM H-RN or 1.5 mM H-RN
for 24 h. A-D: Cell cycle distribution analysis by flow cytometry. Ordinate represents cell number, abscissa represents DNA content. The first sharp
peak represents G0/G1 phase cells, the following lower peak represents G2/M phase cells, and the area between them represents S phase cells.
The numbers on the right part of each figure represent the percentage of cells in each phase. A: control group; B: 100 ng/ml VEGF group; C: 150
μM H-RN group; D: 1.5 mM H-RN group. E-G: Statistical analysis among different groups. E: Statistical analysis of the percentage of G0/G1 phase
cells among different groups; F: Statistical analysis of the percentage of S phase cells among different groups; G: Statistical analysis of the
percentage of G2/M phase cells among different groups. (*p<0.05 versus no VEGF control group).
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Thermo, Waltham, MA).
Cell proliferation assay
Cell proliferation assays were performed as previously
described [16,25] using the CellTiter96 AQueous One Solu-
tion Cell Proliferation Assay (MTS) kit (Promega, Madison
WI, USA) according to the manufacturer’s instructions.
Briefly, cells were seeded into 96-well plates (4.8×103cells/
well). After 24 h, cells were serum-starved overnight and
treated with 100 ng/ml human VEGF (Sigma-Aldrich, USA)
and increasing concentrations of H-RN (0, 1 μM,
10 μM, 100 μM or 1 mM) in 100 μL of serum free medium
for 24 h. Following treatment, 20 μl of MTS reagent was
added to each well and incubated for 4 h. The absorbance at
490 nm was recorded using a microplate reader (BIO-RAD,
Model 680, USA). Each group was tested in triplicate and
assays were repeated a minimum of three times.
Cell migration assay
Cell migration assays were performed as previously
described with modifications [16,26]. Briefly, HUVECs werestarved overnight, trypsinized and suspended at a final
concentration of 5×105 cells/ml. Cells were pre-incubated
with various concentrations of peptides for 30 min at 37°C
before seeding into Transwell chambers (tissue culture
treated, 10 mm diameter, 8.0 μm pores; Corning Inc. New
York, N.Y., USA), Cells (5×104) were seeded onto the upper
Transwell chamber and VEGF (100 ng/ml) was placed into
the lower chamber. The assembled cell culture insert
chamber was then incubated at 37°C for 24 h. After
removal of non-migrating cells in the upper chambers with
a cotton swab, migrated cells on the lower surface of the
porous membrane were fixed, stained with Gram’s stain
and photographed under a light microscope (Olympus,
Tokyo, Japan). Five random fields (×200) were chosen in
each insert and the cell number was quantified manually.
Each experiment was repeated 3 times.
Endothelial cell tube formation assay
Tube formation assays to assess the formation of vascular-
like structures by HUVECs on growth factor-reduced
Matrigel (BD Biosciences) were performed as previously
described [16,27]. Cells (2.5×104) were pre-incubated with
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seeded into 96-well culture plates pre-coated with Matrigel
in serum free medium containing VEGF (100 ng/ml) and
incubated at 37°C for 18 h. Tube formation was observed
using an inverted phase contrast microscope (Olympus,
Tokyo, Japan). Images were captured with a digital camera
(Olympus, Tokyo, Japan). The degree of tube formation
was quantified by measuring the length of tubes in three
randomly chosen low power fields (×100) from each well
using the Image-Pro Plus Program (version 5.1, Media
Cybernetics, Inc. America). Each group was tested in
triplicate. Each experiment was repeated 3 times.
Corneal neovascularization model
Male C57BL/6J mice (7-9 weeks old) were obtained from
the Shanghai Laboratory Animal Centre, Chinese Academy
of Sciences. All experiments were consistent with the
ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. The animals were divided into four
groups. A corneal micropocket assays were performed as
previously described on one eye of each mouse [19,28]
using pellets comprising the slow-release polymer Hydro
(polyhydroxyethylrnethacrylate [polyHEMA]) and sucral-
fate. 0.5 μl PBS containing 160 ng VEGF or not was added
on to each pellet. Pellets containing VEGF were then
resuspended with 1 μg or 5 μg of peptides, and these pellets
were only used in VEGF treated group, while pellets
containing PBS were used in control group. All pellets were
dried under sterile air before storage in 4°C. Mice were
anesthetized with 2% chloralhydrate and an intrastromal
pocket was surgically created in the cornea. A slow release
pellet was inserted into the intrastromal pocket (VEGF,
control, 1 μg peptides, 5 μg peptides; n=8 mice per group,
32 mice total). Ofloxacin ointment was applied to the
operated eye in order to release the irritation and prevent
infection. On post-operative day 7, mice were anesthetized,
and the corneas were microscopically examined using an
Olympus SZX2-ILLT stereoscope. Corneal neovascular-
ization was evaluated by measuring the maximal vessel
length from limbal vasculature toward the pellet (R1;
in mm) and the contiguous circumferential zone of neovas-
cular clock hours (R2). The neovascular area was calculated
by the formula: Area (mm2) = 0.5×3.14×R1×R2×0.4 (mm).
Flow cytometry assay
HUVECs were seeded in 6-well plates (6×104 cells/well).
After overnight starvation, cells were incubated with VEGF
(100 ng/ml) in ECM culture medium (Gibco, USA). For
treatment with peptides, cells were pre-incubated with
H-RN (150 μM or 1.5 mM) or scrambled peptide for 30
min prior to addition of VEGF (100 ng/ml). Cells were
incubated for 24 h and apoptosis was analyzed by annexin
V-FITC / propidium iodide (PI) staining according to the
manufacturer’s instructions (Invitrogen, USA). Briefly, cellswere rinsed with ice-cold PBS and resuspended at a final
concentration of 2-5×105/ml in 250 μl binding buffer. Five
microliters of annexin V-FITC stock solution was added to
the cells and rinsed for 3 minutes at 4°C. Then 10μl PI
(20μg/ml) was added and incubated in the dark at room
temperature for 10 min. Cells were analyzed by flow
cytometry (FACS Calibur, BD Biosciences, Franklin Lanes,
NJ, USA) equipped with Cell Quest software. For each
sample, approximately 1×104 cells were analyzed [29].
Cell cycle analysis
HUVECs were seeded on 6-well plates and incubated with
or without 100ng/ml VEGF 24 h after starvation overnight.
In peptides treated group, cells were incubated with
150 μM or 1.5mM H-RN for 24 h. HUVECs were
harvested, washed with PBS and fixed with 70% ethanol for
30 min at 4°C. Cells were washed once with PBS, and
incubated in PBS containing 50 μg/ml PI, 200 μg/ml RNase
A and 0.1% Triton for 30 min at 37°C in dark. Cells were
analyzed by flow cytometry (FACS Calibur, BD Biosciences,
Franklin Lanes, NJ, USA), and the data analysis was
performed using Cell Quest software [30,31].
Statistical analysis
For experiments with four treatment groups and various
treatment concentrations, univariate analysis of variance
was used. For comparison of the differences between
groups, a posthoc LSD test was used. All values are
expressed as the mean ± SD. An alpha level of <0.05 was
used as the criterion of significance.
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